DEF 14A: Cartesian Growth Corporation II Seeks Extension to Complete Business Combination, Proposes Amendments to Charter

Cartesian Growth Corporation II is seeking shareholder approval to extend the deadline for completing a business combination from November 10, 2024, to November 5, 2025, and to amend its charter to eliminate certain net tangible asset requirements.

Summary

• Cartesian Growth Corporation II (CGC II) is holding an Extraordinary General Meeting on November 6, 2024, to vote on proposals to extend the date by which it must complete a business combination.
• The company is seeking to extend the deadline from November 10, 2024, to up to November 5, 2025, allowing for monthly extensions, each requiring a deposit by the Sponsor into the trust account.
• For each one-month extension from November 10, 2024, to May 5, 2025, the Sponsor will deposit the lesser of $150,000 or $0.03 per public share outstanding.
• For each one-month extension from May 5, 2025, to November 5, 2025, the Sponsor will deposit the lesser of $250,000 or $0.05 per public share outstanding.
• The company is also proposing to amend its charter to eliminate the requirement to maintain net tangible assets of at least $5,000,001 upon consummation of a business combination.
• Shareholders have the right to redeem their shares in connection with the extension for approximately $11.54 per share, based on the trust account balance as of October 24, 2024.
• The Board unanimously recommends voting for the extension and the charter amendment.
• If the extension is not approved, the company will liquidate, and warrants will expire worthless.

Sentiment

Score: 6

Explanation: The document is neutral in tone, presenting the facts of the proposed extension and charter amendment. The outcome depends on shareholder vote and the company's ability to find a suitable target.

Positives

• The extension provides the company with more time to find and complete a suitable business combination.
• Shareholders have the option to redeem their shares for cash if they do not want to participate in the extension.
• Eliminating the net tangible asset requirement could facilitate the completion of a business combination.
• The Sponsor is willing to invest additional capital to extend the timeline for finding a target.

Negatives

• If the extension is approved, the amount held in the Trust Account will be reduced by withdrawals in connection with any shareholder redemptions.
• The company may need to obtain additional funds to complete its initial business combination, and there can be no assurance that such funds will be available on terms acceptable to the parties or at all.
• If the extension is not approved, the warrants will expire worthless.
• The company expects to be delisted if it does not consummate an initial business combination by May 5, 2025.

Risks

• The company may not be able to find a suitable business combination target within the extended timeframe.
• Shareholder redemptions could leave the company with insufficient cash to complete a business combination.
• The company's securities may be delisted from Nasdaq if it does not complete a business combination by May 5, 2025.
• If the NTA Requirement Amendment Proposal is approved, any failure to meet the initial listing requirements of Nasdaq could result in an inability to list the combined company's ordinary shares and warrants on Nasdaq and the obligation to comply with the penny stock rules and could affect the combined company's cash position following the closing of an initial business combination.
• The company may be deemed an investment company under the Investment Company Act of 1940, which could restrict its activities and lead to liquidation.

Future Outlook

The company plans to continue seeking a business combination if the extension is approved and expects to hold another shareholder meeting to approve a specific transaction.

Management Comments

• The Board believes that there may not be sufficient time before the Current Termination Date to complete an initial business combination.
• The Board has determined that it is in the best interests of our shareholders to extend the date by which the Company must complete an initial business combination to the Extended Date.

Industry Context

This announcement is typical for SPACs approaching their deadline to complete a business combination, reflecting the challenges in finding suitable targets and securing shareholder approval.

Comparison to Industry Standards

• Many SPACs seek extensions to provide more time to find a suitable target, a common practice in the industry.
• The redemption price of approximately $11.54 per share is consistent with the typical trust value in SPACs.
• The Sponsor's commitment to deposit additional funds into the trust account is a common mechanism to incentivize shareholders to approve the extension.
• Comparable companies include other SPACs that have sought extensions, such as [hypothetical SPAC A] and [hypothetical SPAC B], which faced similar challenges and required sponsor funding to extend their timelines.

Related Party Transactions

• The Sponsor will deposit funds into the trust account for each monthly extension.
• The Sponsor will continue to receive $10,000 per month for office space, administrative, and support services.

Stakeholder Impact

• Shareholders can choose to redeem their shares or remain invested in the company.
• If the extension is not approved, shareholders will receive a pro-rata share of the trust account, but warrants will expire worthless.
• The Sponsor's investment is at risk if a business combination is not completed.

Next Steps

• Shareholders will vote on the extension and charter amendment proposals on November 6, 2024.
• If the extension is approved, the company will continue to seek a business combination target.
• The company will hold another shareholder meeting to approve a specific business combination if a target is identified.

Key Dates

Keywords

business combination, extension, redemption, SPAC, liquidation, trust account, shareholders, amendment, warrants, sponsor, CGC II, NTA